Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Novo provides update on the denecimig Biologics License Application (BLA) in the USCompanies: Novo NordiskBagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA.
- Novo Nordisk A/S - share repurchase programmeCompanies: Novo NordiskBagsværd, Denmark, 28 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
- Novo and UNICEF expand partnership to support a healthier start for more than 80 million childrenCompanies: Novo NordiskNovo Nordisk and UNICEF expand global partnership, committing USD 18 million to prevent childhood overweight and obesity for more than 80 million children.
- Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia ACompanies: Novo NordiskEMA has adopted a positive opinion recommending marketing authorisation for FREHEMGO® (denecimig) to treat haemophilia A (HA), with or without inhibitors
- Novo and Anthropic will collaborate to advance drug discovery with ClaudeCompanies: Novo NordiskNovo and Anthropic collaboration will help Novo accelerate the development of new medicines and advance AI-driven software development
- Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026Companies: Novo NordiskNovo to share real-world and clinical data including Wegovy® pill and cardiometabolic pipeline progress with next-generation amylin treatments at EASD
- Novo Nordisk A/S - share repurchase programmeCompanies: Novo NordiskBagsværd, Denmark, 07 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
- Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modificationCompanies: Novo NordiskSTEP Young data show 40.4% of children treated with semaglutide and lifestyle modification were no longer classified as having obesity.